PSORIATIC ARTHRITIS TREATMENT MARKET ANALYSIS

Psoriatic Arthritis Treatment Market Size and Trends

Global psoriatic arthritis treatment market is estimated to be valued at USD 11.10 Bn in 2024 and is expected to reach USD 21.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global psoriatic arthritis treatment market growth is driven by rising prevalence of psoriatic arthritis across the world. Technological advancements in diagnosis and treatment of psoriatic arthritis have led to development of newer drug classes such as interleukin inhibitors, which have improved clinical outcomes and quality of life of patients. Rising awareness regarding early diagnosis and treatment of psoriatic arthritis can drive the market growth during the forecast period. However, high costs associated with biologic drugs for psoriatic arthritis treatment and patent expiries of blockbuster drugs can hamper the market growth.

Market Driver - Rising prevalence of psoriatic arthritis

According to latest available estimates, nearly 30 million people worldwide suffer from psoriasis. Out of which, approximately 30% of patients suffer from psoriatic arthritis (PsA). PsA causes inflammation and stiffness in and around the joints, and can severely impact the quality of life. Factors like genetic predisposition, excessive weight, smoking, and certain gut diseases have been linked to higher risks of developing psoriasis and PsA. With rising global prevalence of psoriasis and increasing awareness, more and more people are being diagnosed with PsA each year.

Most physicians earlier assumed PsA to be a minor issue or a precursor to psoriasis but now clearly recognize it as a chronic inflammatory disease requiring long term treatment approach. Improved diagnostic methods allow early detection and monitoring of joint damage. Population based studies show that nearly 50% of patients experience PsA onset before psoriasis, indicating delayed diagnosis is often the case. Even in developed markets, many patients have undiagnosed PsA for years, which has caused permanent joint damage by the time it was detected. Growing health impacts of PsA in terms of physical disability, impaired body functions, and mental health issues compel patients to seek treatment options.

Increasing R&D investments by key players

Top pharmaceutical players have recognized the commercial potential in developing innovative therapeutics for psoriatic arthritis due to  its large underserved patient base across global markets. Massive R&D spending in recent years on target pathway drug development specifically for PsA has generated positive clinical outcomes. Successful approval and uptake of novel biologics has validated the need for more effective treatment alternatives beyond traditional disease-modifying anti-rheumatic drugs (DMARDs).

Complex molecular pathways associated with chronic inflammation in PsA present multiple lucrative therapeutic targets. Advance research on genes, biomarkers and immunological mechanisms driving PsA pathogenesis have opened up new directions for precision therapies. Companies are exploring monoclonal antibodies, small molecule inhibitors and cell/gene therapies focused on specific targets involved in immune system dysregulation and cytokine signaling linked to PsA. First-in-class new chemical entities achieving superior efficacy with better safety profiles than existing drugs offer a competitive strategic advantage and market exclusivity.

Several big pharma companies have set up dedicated research divisions and global clinical trial networks to expedite development while accessing diverse patient pools. Higher R&D budgets and strategic collaborations allow testing diverse treatment paradigms for better disease modification and functional restoration in joints. First-mover products entering a space deficient in solutions could corner a major share of the PsA market in the long run.